Debiopharm, founded in 1979 by Dr. Rolland-Yves Mauvernay, is a privately-held Swiss biopharmaceutical company headquartered in Lausanne, Switzerland. The company focuses on the development and clinical testing of innovative drug candidates, with a mission to advance treatments that improve patient outcomes worldwide. Debiopharm offers products such as Triptorelin and Oxaliplatin, targeting various therapeutic areas including oncology and infectious diseases. Additionally, the Debiopharm Innovation Fund SA invests strategically in digital health initiatives.
Notable figures affiliated with Debiopharm include Thierry Mauvernay, President, Bertrand Ducrey, CEO of Debiopharm International SA, and Marc Cikes, Managing Director of the Debiopharm Innovation Fund SA. The company has achieved significant milestones in drug development and commercialization, contributing to the global healthcare landscape. Through its innovative therapies and strategic investments in digital health, Debiopharm has made a substantial impact on improving patient care and advancing medical research.
